INZY - Inozyme Pharma, Inc.
IEX Last Trade
2.925
-0.010 -0.342%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$2.94
-0.01
-0.34%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.01%
1 Month
10.98%
3 Months
-43.11%
6 Months
-32.95%
1 Year
-33.71%
2 Year
144.17%
Key data
Stock price
$2.92
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.62 - $7.80
52 WEEK CHANGE
-$34.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Axel Bolte
Region: US
Website: inozyme.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inozyme.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Inozyme Pharma, Inc. engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.
Recent news